Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.42 |
| ▸ | TSHR | P16473 | 7/20 | 0.42 |
| ▸ | MEN1 | O00255 | 7/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.42 |
| ▸ | BLM | P54132 | 5/20 | 0.42 |
| ▸ | GAA | P10253 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 5/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.42 |
| ▸ | RECQL | P46063 | 3/20 | 0.42 |
| ▸ | GMNN | O75496 | 3/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9501236 | 0.79 | CA2 (0.48) | ALDH1A1TSHRMEN1KMT2AMAPT | |
| SCHEMBL13522250 | 0.74 | CA2 (0.56) | ALDH1A1TSHRMEN1KMT2AMAPT | |
| SCHEMBL1962153 | 0.72 | CA2 (0.54) | ALDH1A1TSHRMEN1KMT2AMAPT | |
| SCHEMBL6858911 | 0.72 | CA2 (0.54) | ALDH1A1TSHRMEN1KMT2AMAPT | |
| SCHEMBL4710701 | 0.72 | CA2 (0.54) | ALDH1A1TSHRMEN1KMT2AMAPT | |
| SCHEMBL5362128 | 0.72 | MEN1 (0.56) | ALDH1A1TSHRMEN1KMT2AMAPT | |
| SCHEMBL5362140 | 0.72 | MEN1 (0.56) | ALDH1A1TSHRMEN1KMT2AMAPT | |
| SCHEMBL5362134 | 0.72 | MEN1 (0.56) | ALDH1A1TSHRMEN1KMT2AMAPT | |
| SCHEMBL5459294 | 0.72 | MAPT (0.40) | ALDH1A1TSHRMEN1KMT2AMAPT | |
| Ammonia Solution, Strong SCHEMBL25385967 | 0.71 | CA2 (0.52) | ALDH1A1TSHRMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004799-A1 | Novel compounds for the treatment of obesity | NOVO NORDISK A/S (DK) | 2007-01-04 | — | — | US | claimed |
| EP-1689707-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2006-08-16 | — | — | EP | claimed |
| WO-2005051900-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2005-06-09 | — | — | WO | claimed |
| EP-1625112-B1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20070004799-A1 | Novel compounds for the treatment of obesity | NOVO NORDISK A/S (DK) | 2007-01-04 | — | — | US | disclosed |
| US-20070004799-A1 | Novel compounds for the treatment of obesity | NOVO NORDISK A/S (DK) | 2007-01-04 | — | — | US | disclosed |
| US-20070004799-A1 | Novel compounds for the treatment of obesity | NOVO NORDISK A/S (DK) | 2007-01-04 | — | — | US | disclosed |
| EP-1689707-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2006-08-16 | — | — | EP | disclosed |
| US-20060128662-A1 | Novel compounds for treatment of obesity | NOVO NORDISK A/S (DK) | 2006-06-15 | — | — | US | disclosed |
| EP-1625112-A1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2006-02-15 | — | — | EP | disclosed |
| WO-2005051900-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2005-06-09 | — | — | WO | disclosed |
| WO-2004101505-A1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004799-A1 | Novel compounds for the treatment of obesity | GPR119, NR4A3, NR4A1 | ALDH1A1 1895/4885TSHR 133/4885MEN1 4657/4885 |
| US-20060128662-A1 | Novel compounds for treatment of obesity | GPR119, FABP4, HSD17B4 | ALDH1A1 66/4885TSHR 2048/4885MEN1 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.